CYTOSORBENTS CORPORATION (CTSO) Free cash flow 2016–2025
CYTOSORBENTS CORPORATION (CTSO) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$12.5MFY2025 · since FY2016: -$6.9M → -$12.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$12.5M | +14.8% |
| FY2024 | -$14.7M | +33.7% |
| FY2023 | -$22.2M | +35.3% |
| FY2022 | -$34.3M | -94.5% |
| FY2021 | -$17.6M | -179.1% |
| FY2020 | -$6.3M | +63.8% |
| FY2019 | -$17.5M | -51.6% |
| FY2018 | -$11.5M | -54.5% |
| FY2017 | -$7.5M | -8.4% |
| FY2016 | -$6.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More CTSO financial trends
CTSO RevenueCTSO Net incomeCTSO Net marginCTSO Gross profitCTSO Gross marginCTSO Operating incomeCTSO Operating marginCTSO Operating cash flowCTSO Capital expendituresCTSO Return on equityCTSO Stock buybacksCTSO Dividends paidCTSO Total assetsCTSO Total liabilitiesCTSO Shareholders’ equityCTSO overview →